In short
A groundbreaking clinical trial is underway to assess the safety, tolerability, and effectiveness of a new hepatitis B vaccine called MVA-HBVac. This innovative vaccine is being tested in adult patients with chronic hepatitis B, offering hope for improved treatment options. The study, known as TherVacB, is a multi-center phase 1b/2a trial that aims to explore the potential of this therapeutic vaccine in combating chronic hepatitis B infection.
At a glance
- Trial Name
- TherVacB
- Trial Phase
- Phase 1b/2a
- Target Condition
- Chronic hepatitis B
- Vaccine Name
- MVA-HBVac
- Administration Route
- Intramuscular injection
- Primary Objectives
- Safety and tolerability assessment
- Secondary Objectives
- Antiviral effect and immunogenicity evaluation
- Key Inclusion Criteria
- Adults 18-70 years, confirmed chronic HBV, on NUC treatment for ≥6 months
- Key Exclusion Criteria
- Advanced liver fibrosis, cirrhosis, hepatocellular carcinoma, coinfections
- Primary Endpoints
- Adverse events, reactogenicity, liver toxicity
- Secondary Endpoints
- HBsAg reduction, anti-HBs induction, T-cell responses
What is MVA-HBVAC?
MVA-HBVAC is a new therapeutic vaccine being developed to treat chronic hepatitis B. It is part of a treatment approach called TherVacB, which combines different types of vaccines to boost the immune system's response against the hepatitis B virus. The vaccine is currently being studied in a clinical trial to assess its safety and effectiveness in adult patients with chronic hepatitis B.
Target Condition: Chronic Hepatitis B
Chronic hepatitis B is a long-lasting liver infection caused by the hepatitis B virus. It can lead to serious liver problems if left untreated. Current treatments can control the virus but rarely cure the infection completely. MVA-HBVAC aims to help the body's immune system fight the virus more effectively.
How MVA-HBVAC Works
MVA-HBVAC is part of a "heterologous prime/boost" vaccination strategy. This means it's used in combination with other vaccine components: Prime: First, patients receive a protein-based vaccine to "prime" the immune system. Boost: Then, MVA-HBVAC is given to "boost" the immune response further. This approach aims to stimulate a stronger and more effective immune response against the hepatitis B virus.
Clinical Trial Details
The clinical trial for MVA-HBVAC, called TherVacB, is a Phase 1b/2a study. This means it's an early-stage trial focused on: Assessing the safety and tolerability of the vaccine Evaluating how well the immune system responds to the vaccine Measuring the vaccine's effect on the hepatitis B virus The trial is being conducted at multiple medical centers, involving adult patients with chronic hepatitis B.
Eligibility Criteria
To participate in the trial, patients must meet certain criteria. Some key requirements include: Age 18-70 years Confirmed chronic hepatitis B infection for at least 6 months Currently on hepatitis B treatment (nucleos(t)ide analogs) for at least 6 months Low levels of hepatitis B virus in the blood No advanced liver disease or other significant health problems There are also several exclusion criteria, such as co-infection with other viruses like HIV or hepatitis C.
Potential Benefits
The researchers hope that MVA-HBVAC, as part of the TherVacB treatment, will: Reduce levels of hepatitis B surface antigen (HBsAg) in the blood Stimulate the production of protective antibodies against hepatitis B Increase the number and activity of immune cells that can fight the virus These outcomes could potentially lead to better control of the hepatitis B infection and improved liver health.
Safety Considerations
As with any new treatment, safety is a top priority. The trial will closely monitor: Side effects at the injection site and throughout the body Any serious adverse events Liver function to ensure the vaccine doesn't cause liver damage Patients in the trial will be regularly checked and tested to ensure their safety throughout the study.